Journal Home
Search for

Volume 65, Issue 3, Pages 283-290 (1 February 2002)


View previous. 9 of 13 View next.

Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis

Magı́ FarréadCorresponding Author Informationemail address, Anna Masa, Marta Torrensb, Vı́ctor Morenocd, Jordi Camı́ae

Received 12 September 2000; accepted 29 May 2001.

Abstract 

The efficacy of methadone maintenance in opioid addiction was assessed in terms of programme retention rate and reduction of illicit opioid use by means of a meta-analysis of randomised, controlled and double blind clinical trials. The results were compared with interventions using buprenorphine and levo-acetylmethadol (LAAM). Trials were identified from the PubMed® database from 1966 to December 1999 using the major medical subject headings ‘methadone’ and ‘randomised controlled trial’. Data for a total of 1944 opioid-dependent patients from 13 studies were analysed. Sixty-four percent of patients received methadone, administered either as fixed or adjusted doses. Thus, 890 patients received ⩾50 mg/day (high dose group) and 392 were given <50 mg/day (low dose group). Of 662 controls, 131 received placebo, 350 buprenorphine (265 at doses ⩾8 mg/day and 85 at doses <8 mg/day) and 181 LAAM. High doses of methadone were more effective than low doses in the reduction of illicit opioid use (odds ratio [OR] 1.72, 95% confidence interval [CI] 1.26–2.36). High doses of methadone were significantly more effective than low doses of buprenorphine (<8 mg/day) for retention rates and illicit opioid use, but similar to high doses of buprenorphine (⩾8 mg/day) for both parameters. Patients treated with LAAM had more risk of failure of retention than those receiving high doses of methadone (OR 1.92, 95% CI 1.32–2.78). It is proposed that in agonist-maintenance programmes, oral methadone at doses of 50 mg/day or higher is the drug of choice for opioid dependence.

a Pharmacology Unit (Institut Municipal d'Investigació Mèdica-IMIM), Carrer Doctor Aiguador 80, E-08003, Barcelona, Spain

b Drug Dependence-Psychiatric Research Unit (Hospital del Mar-IMIM), Paseo Marı&#x0301;timo 25, 08003 Barcelona, Spain

c Unit of Epidemiology (Institut Català d'Oncologia-ICO), Gran Via km 2.7, 08907 Hospitalet de Llobregat, Barcelona, Spain

d Universitat Autònoma de Barcelona, Edifici M, 08193 Bellaterra, Barcelona, Spain

e Universitat Pompeu Fabra, Doctor Aiguader 80, 08003 Barcelona, Spain

Corresponding Author InformationCorresponding author. Tel.: +34-93-2211-009; fax: +34-93-2211-3237

PII: S0376-8716(01)00171-5


View previous. 9 of 13 View next.